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Abstract
Introduction: A body of studies suggests the role of osteopontin (OPN) in onset and development of
osteoarthritis (OA), however, the association between OPN polymorphisms and OA susceptibility as well as its
clinical features has not been reported.
Methods: A total of 750 patients with primary knee OA and 794 healthy volunteer were enrolled as controls. Both
OA and control groups were interviewed to obtain demographic and clinical data. Three polymorphisms of OPN
gene, namely, -156GG/G, -443C/T and -66T/G were determined. The levels of the full length and the thrombin-
cleaved OPN in synovial fluid (SF) from OA subjects were measured.
Results: We found the polymorphisms of the -443C/T and the -66/T/G were significantly associated with the OA
risk and the radiographic severity. The -443TT and -66GG showed protective effect against developing OA and
were associated with lower Kellgren-Lawrence grade. Besides, the polymorphisms of -443C/T and -66T/G
significantly affected the thrombin-cleaved OPN levels in SF from OA subjects. Subjects with -443TT and -66GG
genotypes had lower thrombin-cleaved OPN levels in SF. The thrombin-cleaved OPN levels in SF were positively
correlated to the radiographic severity of OA.
Conclusions: Our findings suggest that certain OPN gene polymorphisms may be used as molecular markers for
the susceptibility and severity of OA.
Introduction
Osteoarthritis (OA) is a degenerative joint disorder result-
ing in substantial morbidity and disability in the elderly
[1,2]. It is now accepted that the excessive, spontaneous
production of cytokines and mediators of inflammation
plays a significant role in the molecular pathogenesis of
OA, contributing to a highly catabolic state, chondrocyte
apoptosis, and the resultant progressive degeneration of
articular cartilage [3-5]. The etiology of OA is largely
unknown. Aging, trauma, hormonal and mechanical fac-
tors are reported to contribute to the onset and progres-
sion of OA [6-8]. Inheritance studies involving family
groups and twin pairs have demonstrated that a large pro-
portion of OA cases can be attributed to genetic factors,
suggesting that the etiology of OA clearly has a genetic
component [9,10]. In recent years, a number of gene poly-
morphisms involved in development of knee OA have
been identified, such as those localized in, or adjacent to
the encoding sequences for the vitamin D receptor [11],
estrogen receptor alpha [12] or calcitonin [13].
Osteopontin (OPN) is a matricellular protein that
through interactions with its receptors, integrins a4b1,
a9b1, av (b1, b3, b5), and CD44 variants, participates in a
wide range of physiologic and pathologic processes,
including wound healing, bone turnover, tumor genesis,
inflammation, and immune responses [14-17]. The asso-
ciation between OPN and joints had been studied. OPN
expression during chondrocyte maturation is one of the
important events involved in cartilage-to-bone transitions,
and OPN is reportedly involved in the molecular patho-
genesis of OA, contributing to progressive degeneration of
articular cartilage [18]. Clinically, OPN in plasma and
synovial fluid (SF) has been reported to be related to pro-
gressive joint damage in knee OA, suggesting that OPN
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may serve as a biochemical marker for determining disease
severity [18].
The expression of OPN is significantly influenced by
genetic polymorphisms of its promoter [19]. Several poly-
morphisms in the human OPN encoding gene have been
identified in different populations, of which the -156 GG/
G, -443C/T and -66T/G polymorphisms were mostly stu-
died. These OPN genetic polymorphisms have been
reported to be associated with inflammatory disease,
such as systemic lupus erythematosus [20], chronic hepa-
titis C [21], lupus nephritis [22], and large artery athero-
sclerosis [23].
Although a body of studies suggests the role of OPN in
the onset and development of OA, the association between
OPN polymorphisms and OA susceptibility, as well as its
clinical features, has never been reported. We carried out
a case-control study to clarify whether the abovemen-
tioned genetic polymorphisms in the OPN gene are asso-




A total of 750 patients with primary OA of the knee were
recruited from February 2007 to December 2011. The
diagnosis of knee OA was based on the American College
of Rheumatology criteria [24]. The severity of OA was
evaluated by Kellgren-Lawrence (KL) grade. We enrolled
794 healthy volunteers as controls. Both the OA and con-
trol groups were interviewed to obtain demographic data
and information on all of the established risk factors.
Patients with other etiologies causing knee diseases, such
as inflammatory arthritis (rheumatoid, polyarthritic, or
autoimmune disease), post-traumatic or post-septic arthri-
tis, skeletal dysplasia or developmental dysplasia were
excluded from the OA group.
All the controls were enrolled in this study based on the
following: 1) no history, or signs or symptoms of arthritis
or joint diseases (pain, swelling, tenderness, or restriction
of movement) and 2) normal appearances on radiography
of the knee. The clinical characteristics of all enrolled sub-
jects, including age, sex, body mass index (BMI), smoking
status, knee activity and regular exercise were recorded.
Obesity was defined as BMI > 30 kg/M2. The study was
approved by the ethics review committee of Harbin Medi-
cal University and written informed consent was obtained
from all participants.
OPN gene polymorphisms
DNA was extracted from peripheral whole blood using a
Qiagen DNA Isolation Kit (Qiagen, Valencia, CA, USA).
Three single nucleotide polymorphisms on the promoter
region of OPN gene, including -66T/G (rs28357094),
-156G/GG (rs17524488), and -443C/T (rs11730582), were
determined using TaqMan 5’ allelic discrimination assay.
It was performed using a commercially available kit,
Assays-on-DemandTM single nucleotide polymorphism
(SNP) genotyping products (Applied Biosystems, Foster
City, CA, USA). SNP amplification assays were used
according to the manufacturer’s instructions. In short, 10
ng of sample DNA in 25 μL of reaction solution, contain-
ing 12.5 μL of the 2× TaqMan® Universal PCR Mix
(Applied Biosystems), and 1.25 μL of pre-developed assay
reagent from the SNP genotyping product containing two
primers and two MCB-Taqman probes. The reaction con-
dition consisted of pre-incubation at 50°C for 2 minutes,
and at 95°C for 10 minutes, followed by 40 cycles of 95°C
for 15 s, and 60°C for 1 minute. Amplifications were per-
formed in an ABI Prism® 7500 Sequence Detection
System (Applied Biosystems). To reconfirm the results of
the genotypes, we randomly selected 25 patients and 25
controls (10% of the study subjects) for re-genotyping by
direct sequencing; the results were 100% identical.
OPN level detections
SF was obtained from 175 OA patients; none was obtained
from controls due to ethical concerns. The levels of the
full length and the thrombin-cleaved OPN in SF were
determined by capture ELISA according to the protocol
provided by the manufacturer (Calbiochem, San Diego,
CA, USA). The sensitivity for OPN was 3.33 ng/ml, with
intra- and inter-assay coefficients of variation (CV) of <
5%, and < 10%, respectively [25].
Western blot analysis
A 5-μL aliquot from each sample of SF was subjected to
SDS-PAGE; the separated proteins were electro-trans-
ferred onto polyvinylidene fluoride membranes (Milli-
pore, Bedford, MA, USA). Nonspecific proteins on the
membranes were blocked in 5% skimmed milk powder in
PBS (thrombin-cleaved OPN overnight at 4°C. Immuno-
blotting was performed with use of the rabbit against
human Full length OPN Anti-Osteopontin antibody
(ab8448, 1:1,000 dilution, Abcam, Cambridge, MA, USA)
and thrombin-cleaved OPN antibodies (Mouse Anti-
Human Osteopontin N-Half Monoclonal, 1:1,000 dilu-
tion, Cosmo Bio Co., Ltd., Toyo, Japan). The membranes
were then incubated with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibodies
(1:2,500 dilution). Immunoreactive proteins were visua-
lized with the western blotting luminol reagent (Santa
Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analyses
Chi square (c2) tests were used to compare genotype fre-
quency and demographic distributions between cases and
controls. Multiple logistic regression analysis was used to
evaluate if each SNP was independently associated with
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OA when adjusted for the potential confounding effects
of important clinical variables. The odds ratios (OR) and
95% CIs were calculated. The associations between the
OPN haplotypes and OA risk were analyzed. The D’
value and r2 for the three SNPs that we studied were cal-
culated using SHEsis software [26]. All other analyses
were performed using SPSS software (Statistical Package
for the Social Sciences, version 16.0, SPSS Inc, Chicago,
IL, USA).
Results
Table 1 shows demographic and clinical characteristics
of all subjects in the study. There were no significant
differences in sex, age, smoking status, history of work
involving heavy labor, hypertension, or diabetes mellitus
between knee OA cases and controls. The OA patient
group had a markedly higher BMI than the controls
(P = 0.001).
Table 2 describes the genotype distributions and allele
frequencies of OPN polymorphisms in OA and control
subjects. The genotype frequencies for all polymorphisms
did not differ significantly from those expected under
Hardy-Weinberg equilibrium (both P > 0.05). The geno-
type and allele frequencies at OPN -156/G/GG were simi-
lar in OA and control subjects. In contrast, the -443C/T
and -66/T/G genotype were significantly different between
knee OA subjects and controls. The OA patients had sig-
nificantly lower rates of -443TT and -66GG than controls
(P < 0.001 and P = 0.013, respectively). Accordingly, the
-443T and -66G allele frequencies were lower in OA
patients than in controls (P = 0.018 and P = 0.009, respec-
tively). Logistic regression analysis showed a significantly
decreased risk for knee OA for the -443TT genotype com-
pared with the -443CC genotype (OR 0.525, P < 0.001)
after adjustment for sex, age, smoking status, family his-
tory and history of heavy labor. The adjusted OR for the
-443T allele carriage was 0.689 (P < 0.001). Similarly the
-66GG genotype carriers had a lower risk for OA, as the
adjusted OR was 0.652 (P = 0.017) compared with the
-66TT genotype. The adjusted OR for the -66G allele car-
riage was 0.815 (P = 0.011).
The associations between the OPN haplotypes and
knee OA risk were analyzed in this study. The D’ value
for the three SNPs were calculated with the SHEsis soft-
ware [26]. All three SNPS were in strong linkage dise-
quilibrium (LD) (all D’ > 0.8). The estimated haplotype
frequencies of the OPN SNPs are shown in Table 3. The
haplotype G-156T-443 G-66 represented a protective effect
for developing knee OA (adjusted OR 0.754, P = 0.005).
Meanwhile, the GG-156C-443 T-66 showed a higher risk
for developing OA (OR 1.943, P < 0.001).
We analyzed the genotype and the radiographic severity
of OA in the patient group, who were grouped into sub-
jects with KL grade = < 3 and those with KL grade > 3
(Table 3). We found that the -443C/T and -66T/G geno-
types were significantly different between OA subjects
with KL grade = < 3 and those with KL grade > 3 (both
P < 0.001). Logistic regression analysis showed that the
-66GG genotype and -443TT carriers were less likely to
have severe OA (KL grade > 3) compared with -66TT and
-443CC carriers. The adjusted OR for -443TT carriers was
0.529 (OR 0.664, P = 0.011, with -443CC as the reference)
and the adjusted OR for -66GG carriers was 0.635 (OR
0.757, P = 0.023, with -66TT as the reference). The car-
riage of -443T and -66G represented a protective role
against developing severe OA (adjusted OR 0.659 and
0.732, P = 0.008 and 0.017, respectively) (Table 4). The
genetic polymorphisms of -156G/GG did not influence
the severity of OA.
We further analyzed the correlation between the OPN
level in SF and the radiographic severity of OA. The mean
full length OPN levels were similar among KL grade 2, KL
grade 3 and KL grade 4 subgroups (data not shown). In
contrast, the mean thrombin-cleaved OPN levels in OA
subjects were quite different among these KL-graded sub-
groups. The mean thrombin-cleaved OPN level was, 669.2
Table 1 Demographic and clinical characteristics of all subjects in the study
Variables Cases (n = 750) Control (n = 794) P
Age, years, mean ± SD 65.2 ± 7.6 65.1 ± 5.4 ns
Female, n (%) 401 (53.47%) 406 (51.13%) ns
BMI, kg/m2, mean ± SD 27.7 ± 2.4 22.5 ± 3.1 0.001
Smoker, n (%) 283 (37.73%) 291 (36.65%) ns
Family history of OA, n (%) 60 (8.00%) 67 (8.43%) ns
History of labor work, n (%) 140 (18.66%) 158 (19.89%) ns
Hypertension 198 (26.4%) 206 (25.9%) ns
Diabetes mellitus 152 (20.3%) 166 (20.9%) ns
KL grade
= < 3 351 -
> 3 399 -
BMI, body mass index; OA, osteoarthritis; KL, Kellgren-Lawrence; ns, not significant.
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± 476 (mean ± SD) pg/ml in patients with KL grade 2 OA,
5,203.6 ± 385 pg/ml in those with KL grade 3, and 5,642.7
± 350 pg/ml in those with KL grade 4 (Figure 1). Positive
correlation was found between the thrombin-cleaved OPN
levels (but not the full length OPN levels) in SF and OA
severity (Pearson correlation coefficient 0.692, P < 0.001).
We next analyzed the thrombin-cleaved OPN levels in
SF according to the genotypes of the OPN gene poly-
morphisms. Our results showed that the thrombin-
cleaved OPN levels in SF were significantly lower in
-443TT carriers compared with the -443TC and -443CC
carriers (4,728 ± 354 vs. 5,398 ± 354 and 5334 ± 323,
pg/ml, both P < 0.05). Similarly, the thrombin-cleaved
OPN levels in SF from -66GG were lower than from the
-66GT and -66TT carriers (4,989 ± 329 vs. 5,413 ± 357
and 5,426 ± 274, pg/ml, both P < 0.05). The genetic
polymorphisms of -156G/GG did not influence the
thrombin-cleaved OPN levels in SF (Figure 2). Western
blot results showed that the thrombin-cleaved OPN
expressions in the SF from -443TT patients were mark-
edly lower than that from the -443TC and -443CC
patients. The thrombin-cleaved OPN expressions in the
SF from -66 GG patients were lower than those from
-66GT and -66TT carriers (Figure 3). The protein
expression of full-length OPN levels in SF were similar
among -443TT carriers compared with the -443TC and
-443CC, as well as the -66GG, -66GT and -66TT geno-
type carriers (figure not shown).
Discussion
In this study, we investigated the role of OPN gene poly-
morphisms in determining the susceptibility to, and
radiographic severity of OA in a Chinese cohort. Of three
gene polymorphisms in this study, we found the poly-
morphisms of two loci, namely, the -443C/T and the
-66T/G, were significantly associated with the risk and
radiographic severity of OA. The -443TT and -66GG
polymorphisms showed a protective effect against occur-
rence of OA and were associated with lower radiographic
severity. In addition, the polymorphisms of -443C/T and
-66T/G significantly affected the thrombin-cleaved OPN
levels in SF from OA patients. Patients with the -443TT













95% CI Adjusted P-
value
-156/G/GG GG 203 27.07 213 26.83 0.557 1
GGG 352 46.93 391 49.24 0.956 0.732 1.276 0.701
GGGG 195 26.00 190 23.93 1.787 0.887 1.552 0.674
G 758 50.53 817 51.45 0.318 1
GG 742 49.47 771 48.55 1.038 0.785 1.267 0.658
-443C/T CC 167 22.27 119 14.99 < 0.001 1
CT 384 51.20 405 51.01 0.763 0.457 0.998 0.003
TT 199 26.53 270 34.01 0.525 0.392 0.872 < 0.001
C 718 47.87 643 40.49 0.018 1
T 782 52.13 945 59.51 0.689 0.575 0.896 < 0.001
-66T/G TT 188 25.07 153 19.27 0.013 1
TG 369 49.20 402 50.63 0.738 0.516 0.988 0.035
GG 193 25.73 239 30.10 0.657 0.494 0.874 0.017
T 745 49.67 708 44.58 0.009 1
G 755 50.33 880 55.42 0.876 0.765 0.876 0.011
OPN, osteopontin; OA, osteoarthritis; OR, odds ratio.
Table 3 Associations between OPN haplotypes and risk of knee OA
Haplotype analysis*
-156G/GG -443C/T -66T/G Cases (frequency) Controls (frequency) Chi2 Pearson’s P Odds ratio (95% CI)
G C T 166 194. 4.451 0.065 0.789 (0.633, 1.092)
G T G 218 262 8.044 0.005 0.754 (0.620, 0.917)
G C T 209 206 0.206 0.650 0.953 (0.775, 1.172)
G T G 154 177 3.422 0.064 0.806 (0.642, 1.013)
GG C T 273 145 37.47 0.000 1.943 (1.566, 2.409)
GG C G 222 165 6.324 0.012 1.317 (1.062, 1.633)
GG T T 231 210 0.181 0.670 1.045 (0.854, 1.278)
*All haplotypes with frequency < 0.03 are ignored in this analysis.
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and -66GG genotypes had markedly lower thrombin-
cleaved OPN levels in SF than those with -443CT,
-443CC and -66 GT and -66TT. Moreover, the throm-
bin-cleaved OPN levels in SF were positively correlated
with the radiographic severity of OA. To the best of our
knowledge, this is the first study of the significance of
OPN gene polymorphisms in the susceptibility to, and
severity of OA. Our findings suggest that certain OPN
gene polymorphisms may be used as molecular markers
for susceptibility to, and severity of OA.
OPN is an extracellular matrix protein with pleiotropic
properties, and has been recently recognized as a poten-
tial inflammatory cytokine [27]. Expression of OPN has
been observed in the joints of patients with rheumatoid
arthritis (RA) as well as OA [28]. The function of OPN is
modulated by protease digestion, and a thrombin-cleaved
form of OPN is involved in the pathogenesis of various
inflammatory disorders, including OA and RA [29,25,30].
More than fifty single nucleotide polymorphisms have
been identified in the human OPN encoding gene in dif-
ferent populations [31]. We selected three SNPS based on
previous association with autoimmune and/or inflamma-
tory diseases and ability to determine haplotypes predict-
ing serum OPN concentrations [32,21,33,34]. The SNP at
-66 was predicted to bind the specificity protein 1 (SP1)
transcription factor, as it is known that the sequence
between -68 and -59 is an SP1 binding site in the human
OPN promoter [35]. A previous study showed that SP1
and SP3 factors recognize this site and that the allele with
the -66T nucleotide inside the SP1 recognition sequence
has a higher binding affinity [31]. Among patients with
cancer, those with G/G at -156 have been found to have
higher concentrations of OPN than those with G/GG or
GG/GG. Patients with G/G at -156 have more frequently
been diagnosed with advanced stage than with early stage
non-small cell lung cancer (NSCLC) [36]. Another study
revealed that the functional -443C/T polymorphism influ-
ences OPN gene expression in melanoma cells via binding
of c-Myb transcription factor [37]. To date, these genetic
variations of the OPN gene have been described to be
associated with inflammatory diseases, including lupus
erythematosus, multiple sclerosis, urolithiasis, primary
Table 4 Genotype and the radiographic severity in patients with OA
Genotype KL = < 3, number of
patients










GG 92 26.21 91 22.81 0.462 1
GGG 166 47.29 206 51.63 0.787 0.564 1.178 0.223
GGGG 93 26.50 102 25.56 0.916 0.638 1.376 0.653
G 350 49.86 388 48.62 1
GG 352 50.14 410 51.38 0.934 0.786 1.186 0.648
-443C/T CC 88 25.07 79 19.80 < 0.001 1
CT 176 50.14 188 47.12 0.816 0.537 1.264 0.352
TT 87 24.79 132 33.08 0.664 0.365 0.879 0.011
C 352 50.14 346 43.36 1
T 350 49.86 452 56.64 0.659 0.647 0.948 0.008
-66T/G TT 97 27.64 91 22.81 0.462 1
TG 158 45.01 191 47.87 0.865 0.587 1.234 0.174
GG 96 27.35 117 29.32 0.757 0.438 0.944 0.023
T 332 47.29 373 46.74 1
G 370 52.71 425 53.26 0.7326 0.668 0.973 0.017
KL, Kellgren-Lawrence grade
Figure 1 Mean thrombin-cleaved osteopontin (OPN) levels in
synovial fluid (SF) IN patients with osteoarthritis (OA)
according to Kellgren-Lawrence (KL) grade.
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biliary cirrhosis, and autoimmune lymphoproliferative
syndrome.
Our results in this study showed that the thrombin-
cleaved OPN levels in SF were significantly lower in
-443TT compared with -443TC and -443CC carriers. A
previous study examined the effect of the -443T/C poly-
morphism on transcription of the OPN gene. The authors
measured promoter activity with a dual luciferase repor-
ter assay system and compared the activities of the -443C
and -443T alleles with the MKN28 and SGC-7901 cell
lines. They found significantly higher luciferase activities
were generated with the pGL3-C construct compared to
the pGL3-T construct [38]. A recent study of metastases
in melanoma found that those homozygous for the
-443C allele expressed significantly higher levels of OPN
mRNA compared to those that were either heterozygous
(CT) or homozygous for the -443T allele. Transcription
factor c-Myb binds to the region of the OPN promoter in
an allele-specific manner and induces enhanced activity
of the -443C compared to the -443T OPN promoter [37].
These studies provide information on the mechanism
under which the -443T/C polymorphism regulates the
OPN gene transcript activity, thus influencing OPN
expression.
A study reported that the -66 polymorphism modifies
the binding affinity for the SP1/SP3 transcription factors.
The authors found that SP1 and SP3 factors recognize this
site and that the allele with the T nucleotide inside the
SP1 recognition sequence has a higher binding affinity.
Overexpression of SP1 induced higher promoter activation
on a plasmid carrying the T allele compared with the
equivalent plasmid carrying the G allele. Consistent with
this finding, we found the thrombin-cleaved OPN levels in
SF from -66GG was lower than -66GT and -66TT.
Two previous studies investigated the association
between the OPN gene polymorphisms and RA. Unlike
the reported effect of the OPN SNP conferring predispo-
sition to common diseases such as multiple sclerosis or
systemic lupus erythematosus, four SNPs of the OPN
gene (327T/C, 795C/T, 1128A/G, and 1284A/C) did not
contribute to RA susceptibility in a Spanish population
[39]. Another study in a Chinese population showed that
OPN gene polymorphisms do not correlate with suscept-
ibility to RA [40]. In the present study, we found that the
-443C/T and -66T/G were associated not only with risk
of OA, but also its radiographic severity, suggesting the
role of OPN genetic polymorphisms in OA and RA may
be quite different.
Figure 2 Mean thrombin-cleaved osteopontin (OPN) levels in synovial fluid (SF) according to the genotypes of OPN gene
polymorphisms.
Figure 3 Thrombin-cleaved osteopontin (OPN) levels in synovial fluid (SF) from different genotype carriers. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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Elevated levels of OPN have been found in SF from RA
patients and increased levels of OPN have been correlated
with increased levels of multiple inflammatory cytokines
[28]. A recent study showed that thrombin-cleaved OPN
levels from SF samples correlate with radiographic severity
determined by KL grading of knee OA in a Japanese study
[29]. In that study, immunohistochemistry of the syno-
vium showed stronger reactivity in samples from subjects
with advanced OA. Consistent with this finding, we
observed in the present study that thrombin-cleaved OPN
levels from SF were significantly higher in those with KL
grade > 3 than in those with KL grade = < 3; by stratifying
the thrombin-cleaved OPN levels according to the OPN
genotypes, we found that the -443 and -66 polymorphisms
had a substantial influence on thrombin-cleaved OPN
levels. The -443TT and -66GG, which showed a protective
role against susceptibility to OA, had markedly lower
thrombin-cleaved OPN levels. Our data confirmed the
positive correlation between thrombin-cleaved OPN levels
in SF and OA severity. We suggest that thrombin-cleaved
OPN may serve as a biochemical marker for determining
disease severity and could be predictive of prognosis with
respect to the progression of knee OA. Since previous stu-
dies showed that the alleles at polymorphic sites in the
OPN gene influence the OPN level by influencing the level
of promoter activity and characterizing their ability to
bind transcription factors, we here postulated that the
influence of OPN polymorphisms on risk and severity of
OA is very likely due to its effect on the synthesis of the
active OPN protein.
Some limitations of this study need to be addressed.
First, there was a large proportion of obese patients in
this study. As obesity is an important risk factor for OA,
not only as a mechanical factor but also due to the
related increase in cytokines, which contribute to OA
development. Thus, there might have been enrollment
bias in the recruitment of patients with primary OA
into this study. Second, we enrolled a Chinese cohort of
patients with knee OA only, so, whether the positive
roles of OPN gene polymorphisms we found in this
study exist in other types of OA, or in other ethnic
populations, remains unknown. Third, we did not per-
form functional analyses to further disclose the mechan-
ism under which the OPN gene polymorphisms affect
the susceptibility to and severity of OA.
Conclusions
In this study we found the polymorphisms of two loci of
OPN gene, namely, the -443C/T and the -66T/G, were
significantly associated with risk and radiographic severity
of OA, suggesting that these OPN gene polymorphisms
may be used as molecular markers for the susceptibility to,
and severity of OA.
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